Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort
Abstract Objective Few studies have evaluated disparities in race, ethnicity, and health insurance in real‐world health outcomes for patients with diffuse large B‐cell lymphoma (DLBCL). This study aimed to evaluate association between racial disparities and health insurance with real‐world health ou...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846156144306814976 |
|---|---|
| author | Yanling Jin Jia Li Yong Mun Anthony Masaquel Sylvia Hu Juliana M. L. Biondo |
| author_facet | Yanling Jin Jia Li Yong Mun Anthony Masaquel Sylvia Hu Juliana M. L. Biondo |
| author_sort | Yanling Jin |
| collection | DOAJ |
| description | Abstract Objective Few studies have evaluated disparities in race, ethnicity, and health insurance in real‐world health outcomes for patients with diffuse large B‐cell lymphoma (DLBCL). This study aimed to evaluate association between racial disparities and health insurance with real‐world health outcomes. Methods Patients with DLBCL (January 2011–July 2021) treated with first‐line therapy were selected from a real‐world database. Variables of interest included race/ethnicity, health insurance type (Medicaid, Commercial) by patient age (<65, ≥65 years), stage at diagnosis, overall survival (OS), and time to second‐line therapy or death due to any cause (TTNTD). Results Among 5362 patients with DLBCL (82% White, 7% Black, 8% Hispanic/Latino, 3% Asian), White patients were older (mean age, 66.7 vs. 59.3–62.5 years) and less likely to have Medicaid insurance (1.7% vs. 3.4%–5.9%). Adjusted hazard ratios (aHR) for OS (Black, 0.88 [95% confidence interval, 0.72–1.07]; Hispanic/Latino, 0.84 [0.70–1.03]; Asian, 0.82 [0.59–1.16]) and TTNTD (Black, 0.89 [0.75–1.05]; Hispanic/Latino, 0.85 [0.73–1.00]; Asian, 1.11 [0.86–1.43]) were similar to those of White patients. Among patients aged <65 years, Medicaid‐insured versus Commercially insured patients had more advanced disease (stage III–IV, 66% vs. 48%), worse OS (aHR, 0.52 [0.34–0.80]; p = 0.003), and shorter TTNTD (aHR, 0.70 [0.49–0.99]; p = 0.044). Conclusions There was no statistically significant difference in these variables/outcomes between Medicaid‐insured and commercially insured patients aged ≥65 years. Medicaid‐insured status was significantly associated with poorer OS and TTNTD in patients with DLBCL aged <65 years but not in those aged ≥65 years, with or without adjusting for other baseline characteristics. Race was not significantly associated with these outcomes. |
| format | Article |
| id | doaj-art-09dcfc6c20f04908be14a5e39c035251 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-09dcfc6c20f04908be14a5e39c0352512024-11-26T10:12:30ZengWileyCancer Medicine2045-76342024-08-011316n/an/a10.1002/cam4.70032Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohortYanling Jin0Jia Li1Yong Mun2Anthony Masaquel3Sylvia Hu4Juliana M. L. Biondo5F. Hoffmann‐La Roche Ltd Mississauga Ontario CanadaGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAAbstract Objective Few studies have evaluated disparities in race, ethnicity, and health insurance in real‐world health outcomes for patients with diffuse large B‐cell lymphoma (DLBCL). This study aimed to evaluate association between racial disparities and health insurance with real‐world health outcomes. Methods Patients with DLBCL (January 2011–July 2021) treated with first‐line therapy were selected from a real‐world database. Variables of interest included race/ethnicity, health insurance type (Medicaid, Commercial) by patient age (<65, ≥65 years), stage at diagnosis, overall survival (OS), and time to second‐line therapy or death due to any cause (TTNTD). Results Among 5362 patients with DLBCL (82% White, 7% Black, 8% Hispanic/Latino, 3% Asian), White patients were older (mean age, 66.7 vs. 59.3–62.5 years) and less likely to have Medicaid insurance (1.7% vs. 3.4%–5.9%). Adjusted hazard ratios (aHR) for OS (Black, 0.88 [95% confidence interval, 0.72–1.07]; Hispanic/Latino, 0.84 [0.70–1.03]; Asian, 0.82 [0.59–1.16]) and TTNTD (Black, 0.89 [0.75–1.05]; Hispanic/Latino, 0.85 [0.73–1.00]; Asian, 1.11 [0.86–1.43]) were similar to those of White patients. Among patients aged <65 years, Medicaid‐insured versus Commercially insured patients had more advanced disease (stage III–IV, 66% vs. 48%), worse OS (aHR, 0.52 [0.34–0.80]; p = 0.003), and shorter TTNTD (aHR, 0.70 [0.49–0.99]; p = 0.044). Conclusions There was no statistically significant difference in these variables/outcomes between Medicaid‐insured and commercially insured patients aged ≥65 years. Medicaid‐insured status was significantly associated with poorer OS and TTNTD in patients with DLBCL aged <65 years but not in those aged ≥65 years, with or without adjusting for other baseline characteristics. Race was not significantly associated with these outcomes.https://doi.org/10.1002/cam4.70032diffuse large B‐cell lymphomaMedicaid insurance statusoverall survivaltime to second‐line therapy or death |
| spellingShingle | Yanling Jin Jia Li Yong Mun Anthony Masaquel Sylvia Hu Juliana M. L. Biondo Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort Cancer Medicine diffuse large B‐cell lymphoma Medicaid insurance status overall survival time to second‐line therapy or death |
| title | Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort |
| title_full | Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort |
| title_fullStr | Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort |
| title_full_unstemmed | Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort |
| title_short | Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort |
| title_sort | association of race ethnicity and insurance with survival in patients with diffuse large b cell lymphoma in a large real world cohort |
| topic | diffuse large B‐cell lymphoma Medicaid insurance status overall survival time to second‐line therapy or death |
| url | https://doi.org/10.1002/cam4.70032 |
| work_keys_str_mv | AT yanlingjin associationofraceethnicityandinsurancewithsurvivalinpatientswithdiffuselargebcelllymphomainalargerealworldcohort AT jiali associationofraceethnicityandinsurancewithsurvivalinpatientswithdiffuselargebcelllymphomainalargerealworldcohort AT yongmun associationofraceethnicityandinsurancewithsurvivalinpatientswithdiffuselargebcelllymphomainalargerealworldcohort AT anthonymasaquel associationofraceethnicityandinsurancewithsurvivalinpatientswithdiffuselargebcelllymphomainalargerealworldcohort AT sylviahu associationofraceethnicityandinsurancewithsurvivalinpatientswithdiffuselargebcelllymphomainalargerealworldcohort AT julianamlbiondo associationofraceethnicityandinsurancewithsurvivalinpatientswithdiffuselargebcelllymphomainalargerealworldcohort |